Christopher H Goss

7PUBLICATIONS
22CO-AUTHORS
MortalityMedical infection agents (incl. prions)Pacific Peoples theory of change models for healthCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 24, 2026
Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.

Deepthi Nacharaju, Leila R Zelnick, Kathleen J Ramos

|Aug 04, 2023
Cell-Free DNA Detects Pseudomonas aeruginosa Lung Infection in Modulator-treated People with Cystic Fibrosis.

Dustin R Long, Elizabeth A Holmes, Christopher H Goss

|Aug 02, 2023
Lung function decline is mitigated following liver transplantation in people with cystic fibrosis: A retrospective cohort study.

Faisal A Albaiz, Kathleen J Ramos, Jenna Sykes

|Sep 01, 2021
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.

Christopher H Goss, Sonya L Heltshe, Natalie E West

|Dec 25, 2018
CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.

Alex H Gifford, Sonya L Heltshe, Christopher H Goss

|Sep 28, 2018
Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections.

Christopher H Goss, Yukihiro Kaneko, Lisa Khuu

Pageof 2